Despite potentiating RT-induced IFN-β in tumors (Figure 6), prolonged daily ATRi treatment abolishes the peripheral CD8+ T cell response after RT and depletes the tumor infiltrate of CD8+ T cells, in both the CT26 and B16 models (Figure 7). The gene discussed is IFNB1; the disease is neoplasm.